Multiple myeloma is a type of cancer that affects plasma cells, the blood cells involved in the production of antibodies. It is the second most common hematologic cancer, accounting for 2% of all cancers of hematologic origin.
Nov 9, 2022
0
14
Multiple myeloma is a cancer of the bone marrow, with a life expectancy of less than 5 years post-diagnosis. Proteasome inhibitors, the therapeutic backbone of current treatments, are very effective in treating newly diagnosed ...
Jan 12, 2022
0
18
A drug that strips cancer cells of their quest for immortality represents an effective new option for patients with Waldenström macroglobulinemia, including those not helped by the only class of drugs currently approved ...
Nov 19, 2021
0
3
Cytosolic peptide:N-glycanase (NGLY1) is a widely conserved enzyme involved in de–N-glycosylation of N-glycosylated proteins. Mutations in the human NGLY1 gene cause global developmental delay and multisystemic symptoms, ...
Jul 6, 2021
0
5
Misfolding and aggregation of normally soluble proteins are common pathological features of many neurodegenerative diseases, including Alzheimer's, Parkinson's, Creutzfeldt-Jacob and Huntington's diseases. For example, Parkinson's ...
Sep 29, 2020
0
5
Aging is the main risk factor for dementia and Parkinson's disease. As age progresses, toxic protein aggregates pile up in the brain and impair neuronal function. But why does that happen? An international team of scientists ...
Jun 19, 2020
0
116
Squamous cell carcinoma is a very unusual type of cancer. It occurs in many tissues—for example in the lungs, esophagus, pancreas, throat and pharynx, and on the skin. Due to the many mutations in this type of cancer, treatment ...
Mar 10, 2020
0
2
Proteasome inhibitors have significant promise as components of novel combination therapies to treat multidrug-resistant malaria, according to a study published June 6 in the open-access journal PLOS Pathogens by David Fidock, ...
Jun 6, 2019
0
5
(HealthDay)—For patients with multiple myeloma in whom treatment with lenalidomide and a proteasome inhibitor has failed, progression-free survival (PFS) is longer in those receiving the immunostimulatory monoclonal antibody ...
Nov 8, 2018
0
0
The proteasome inhibitor carfilzomib has taken on an increasing role in the treatment of multiple myeloma, but new research from the Abramson Cancer Center of the University of Pennsylvania shows the therapy comes with the ...
Dec 28, 2017
0
6
